Previous Close | 1.1300 |
Open | 1.1000 |
Bid | 1.0700 x 0 |
Ask | 1.1300 x 0 |
Day's Range | 1.1000 - 1.1000 |
52 Week Range | 0.2100 - 1.2200 |
Volume | |
Avg. Volume | 30 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AAJ.BE
AstraZeneca became the latest big pharma to buy a company focused on an emerging approach to fighting cancer known as radiopharmaceuticals. On Tuesday, the Anglo-Swedish pharmaceutical said it is buying Fusion Pharmaceuticals for up to $2.4 billion as part of a plan to accelerate the development of next-generation cancer treatments. With the deal, AstraZeneca joins Eli Lilly, Bristol-Myers Squibb and Novartis in working to develop therapies that can deliver radioactive isotopes directly to cancer cells.
Big pharma’s investments in nuclear medicine highlight how cancer treatment is shifting to targeted approaches.
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.